BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2018-09-30

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Part 1 - Evaluate the real-world implementation of extended prophylaxis with betrixaban in the acutely ill hospitalized medical population Part 2 - Describe patterns of Venous thromboembolism (VTE) prophylaxis in acutely ill medical patients who qualify for extended VTE prophylaxis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH

NCT01651780

Severe Aortic Stenosis Transcatheter Aortic Valve Replacement Aortic Valve Replacement

COMPLETED PHASE3

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

NCT03214172

Venous Thromboembolism

COMPLETED

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

NCT02064439

Pulmonary Embolism Thromboembolism Thrombosis +2 more

COMPLETED PHASE3

Study Evaluating Betrixaban in Pediatric Participants

NCT03346083

VTE Prophylaxis

TERMINATED PHASE1

Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort

NCT04979780

Treatment of Venous Thromboembolism in Cancer Patients Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Thromboses

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Patients at risk of VTE who are prescribed betrixaban to prevent VTE

No interventions assigned to this group

Cohort 2

Patients at risk of VTE who are prescribed betrixaban or other VTE prophylaxis

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

-Part 1 -

1. Hospitalized acutely ill medical patient
2. Patient prescribed betrixaban
3. Signed informed consent

Part 2 -

1. Hospitalized acutely ill medical patient
2. Patient prescribed betrixaban OR must satisfy criteria a and b:

1. Moderately or severely restricted immobility: patient restricted to bed for at least 24 hours (severe) or restricted to bed for at least 12 hours (moderate) during their hospitalization
2. At least One additional risk factor:

Age \> 70 years D-dimer \> 2x institutional Upper Limit of Normal (ULN) Obesity: Body mass index (BMI) \> 30 kg/m2) History of pulmonary embolism (PE) or deep venous thrombosis (DVT) Active cancer (diagnosed, treated, or progressing in the past 6 months) History of thrombophilia Recent trauma or surgery (within 30 days prior to admission) Ongoing hormonal treatment ICU stay 3. Signed informed consent

Exclusion Criteria

* Part 1 - 1. High bleeding risk - any of the following:

1. Patient on dialysis
2. Low platelet count (\<50 per 109/L)
3. Known bleeding disorder (congenital or acquired)
4. Liver disease prohibitive to anticoagulation
5. Bleeding within last 30 days
6. Use of Dual Anti-Platelet Therapy (DAPT)

Part 2

1. Patients who are on another oral anticoagulant (OAC) for any reason at the time of hospitalization and will remain on it
2. Condition requiring use of OAC at admission, other than VTE prophylaxis (eg, acute VTE at admission)
3. High bleeding risk any of the following:

1. Patient on dialysis
2. Low platelet count (\<50 per 109/L)
3. Known bleeding disorder (congenital or acquired)
4. Liver disease prohibitive to anticoagulation
5. Bleeding within last 30 days
6. Use of Dual Anti-Platelet Therapy (DAPT)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No